ストックスクリーナーアプリを入手
202.88
2.43%
-5.05
Biogen Inc (BIIB) 最新ニュース
Biogen earnings on deck: Can Alzheimer’s drugs sustain momentum? By Investing.com - Investing.com Canada
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating - marketscreener.com
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo! Finance Canada
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS - AlphaStreet
BIIB|Biogen Inc|Price:200.140| - TradingKey
(BIIB) Volatility Zones as Tactical Triggers - Stock Traders Daily
Biogen Inc (BIIB) Institutional Confidence - TradingKey
Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB - MarketBeat
Biogen stock trades steady as Alzheimer’s franchise and pipeline shape earnings outlook - Ad-hoc-news.de
Biogen Inc (BIIB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biogen stock trades steady as Alzheimer’s data and revenue trends shape investor focus - AD HOC NEWS
Dimensional Fund Advisors LP Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales? - TradingView
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs - Endpoints News
Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis - TradingKey
First Trust Advisors LP Purchases 108,111 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027 - Endpoints News
At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Biogen CEO: Lessons from Biopharma on Leading Reinvention - WSJ
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg
Biogen (BIIB) to Post Earnings on Wednesday - MarketBeat
Mediolanum International Funds Ltd Invests $1.14 Million in Biogen Inc. $BIIB - MarketBeat
SEB Asset Management AB Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by Swiss National Bank - MarketBeat
Andra AP fonden Has $9.53 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BIIB Maintained by B of A Securities -- Price Target Lowered to $215 - GuruFocus
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
KBC Group NV Raises Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
Lobbying Update: $1,060,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.86% Potential Upside Amid Robust Therapeutic Portfolio - DirectorsTalk Interviews
Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System - MarketBeat
Biogen stock edges higher as Alzheimer’s and neuromuscular pipeline shapes outlook - ad-hoc-news.de
Bank of New York Mellon Corp Lowers Stock Position in Biogen Inc. $BIIB - MarketBeat
AIA Group Ltd Raises Stake in Biogen Inc. $BIIB - MarketBeat
Biogen stock trades steady as Alzheimer’s revenue and pipeline shape valuation - ad-hoc-news.de
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more - Endpoints News
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer - Bloomberg Law News
Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com
Tens of Thousands With Ataxias Can Access Virtual Care - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - The National Law Review
Rx Rundown: Biogen, Neko Health, Roche and more - Medical Marketing and Media
Is Biogen (BIIB) a Buy, Hold, or Sell Right Now - Kavout | AI
Biogen shares slide as diranersen data raise dosing question - The Pharma Letter
0.48%
0.82%
大文字化:
|
ボリューム (24 時間):